Tecentriq extends streak with win in breast cancer trial
Roche’s checkpoint inhibitor Tecentriq helped extend progression-free survival in a Phase 3 study of patients with a hard-to-treat form of…
Roche’s checkpoint inhibitor Tecentriq helped extend progression-free survival in a Phase 3 study of patients with a hard-to-treat form of…